<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> using <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> (<z:chebi fb="0" ids="4356">DFO</z:chebi>) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction </plain></SENT>
<SENT sid="1" pm="."><plain>The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> (n = 274) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) patients (n = 168) patients participating in the Evaluation of Patients' Iron Chelation with <z:chebi fb="0" ids="49005">Exjade</z:chebi> (EPIC) study (NCT00171821); a large-scale 1-year, phase IIIb study investigating the efficacy and safety of the once-daily oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi>, <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>HRQOL and satisfaction, adherence, and persistence to iron chelation therapy (ICT) data were collected at baseline and end of study using the Medical Outcomes Short-Form 36-item Health Survey (SF-36v2) and the Satisfaction with ICT Questionnaire (SICT) </plain></SENT>
<SENT sid="3" pm="."><plain>Compared to age-matched norms, β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients reported lower SF-36 domain scores at baseline </plain></SENT>
<SENT sid="4" pm="."><plain>Low levels of treatment satisfaction, adherence, and persistence were also observed </plain></SENT>
<SENT sid="5" pm="."><plain>HRQOL improved following treatment with <z:chebi fb="0" ids="49005">deferasirox</z:chebi>, particularly among β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> patients </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, patients reported high levels of satisfaction with <z:chebi fb="0" ids="49005">deferasirox</z:chebi> at end of study and greater ICT adherence, and persistence </plain></SENT>
<SENT sid="7" pm="."><plain>Findings suggest <z:chebi fb="0" ids="49005">deferasirox</z:chebi> improves HRQOL, treatment satisfaction, adherence, and persistence with ICT in β-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Improving such outcomes is an important long-term goal for patients with <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
</text></document>